Article Text

PDF
The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity
  1. M P Cancro
  1. Correspondence to:
    M P Cancro
    Department of Pathology, 284 John Morgan Building, University of Pennsylvania School of Medicine, 36th and Hamilton Walk, Philadelphia, PA 19104-6082, USA; Cancro{at}mail.med.upenn.edu

Abstract

The B lymphocyte stimulator (BLyS; also termed BAFF) family of ligands and receptors plays a central role in B lymphocyte development, selection, and homoeostasis. Members of this family can independently influence different B cell subsets, because the interactions between the two ligands and three receptors vary, and the receptors themselves are differentially expressed among developing, naive, and antigen experienced B cell subsets. These properties prompt careful assessment of how ablative therapies may influence the behaviour of upstream or downstream B lineage populations, as well as how the implementation and expectations of therapeutics targeting BLyS family members must be guided by knowledge of the B cell subsets contributing to pathogenesis.

  • APRIL, a proliferation inducing ligand
  • BCMA, B cell maturation antigen
  • BCR, B cell receptor
  • BLyS, B lymphocyte stimulator
  • BR3, BLyS receptor 3
  • TACI, transmembrane activator and calcium modulator and cyclophylin ligand interactor
  • TNF, tumour necrosis factor
  • BLyS
  • ligands
  • receptors
  • targets
  • autoimmunity

Statistics from Altmetric.com

Footnotes

  • Competing interests: none declared

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.